BCPC · Balchem Corporation

Balchem Corporation delivered a strong start to fiscal 2026, achieving record first-quarter net sales, adjusted EBITDA, and net earnings. Revenue growth of 8.1% was broad-based, with all three reporting segments contributing. The Human Nutrition and Health segment, the largest contributor, saw sales increase 8.3% to $171.6 million, driven by higher volumes in both nutrients and food ingredients. The Animal Nutrition and Health segment grew 8.6% to $62.2 million, while the Specialty Products segment increased 4.4% to $34.7 million. Profitability expanded significantly, with consolidated gross margin improving 210 basis points to 37.3%. Management attributed this expansion to sales growth and manufacturing efficiencies, which partially offset raw material inflation. Operating expenses increased by $8.3 million, primarily due to higher compensation-related costs and professional services, but were more than offset by the gross profit expansion. Consequently, earnings from operations grew to $55.6 million. The company maintained a strong financial position, generating $40.1 million in operating cash flow and $33.8 million in free cash flow. Management highlighted the strength and resilience of the business model amid geopolitical and global trade uncertainties, expressing confidence in the long-term growth outlook. Significant capital returns to shareholders included $30.8 million in dividends and $15.7 million in share repurchases during the quarter. The company ended the period with a net leverage ratio of 0.3 times, indicating substantial financial flexibility.